Scharf Investments LLC Acquires Shares of 44,389 Immunome, Inc. (NASDAQ:IMNM)

Scharf Investments LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 44,389 shares of the company’s stock, valued at approximately $471,000.

Several other institutional investors have also made changes to their positions in IMNM. Renaissance Technologies LLC grew its position in Immunome by 105.0% during the 2nd quarter. Renaissance Technologies LLC now owns 93,300 shares of the company’s stock worth $1,129,000 after acquiring an additional 47,782 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Immunome by 34.6% in the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Immunome by 52.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 166,928 shares of the company’s stock valued at $2,020,000 after buying an additional 57,242 shares during the last quarter. Victory Capital Management Inc. boosted its position in Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after buying an additional 237,497 shares during the period. Finally, Intech Investment Management LLC bought a new stake in Immunome during the 3rd quarter worth approximately $219,000. 44.58% of the stock is currently owned by institutional investors.

Immunome Stock Performance

IMNM opened at $11.03 on Friday. Immunome, Inc. has a one year low of $8.97 and a one year high of $30.96. The company has a fifty day moving average price of $11.36 and a 200-day moving average price of $12.73.

Insider Buying and Selling at Immunome

In other Immunome news, CTO Philip Tsai acquired 21,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were purchased at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at $198,030. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average cost of $9.54 per share, with a total value of $630,183.78. Following the purchase, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This trade represents a 15.74 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 102,862 shares of company stock worth $978,045 over the last three months. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Stephens started coverage on shares of Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler dropped their price target on Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $28.60.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.